CRESCENT BIOPHARMA INC (CBIO)
Health Care · biotechnology · NASDAQ
A clinical-stage oncology biotech developing a PD-1 x VEGF bispecific antibody backbone and a portfolio of antibody-drug conjugates to treat solid tumors.
What CRESCENT BIOPHARMA INC does
Crescent Biopharma is a clinical-stage biotechnology company focused on developing oncology therapies. Its strategy centers on the development of CR-001, a PD-1 x VEGF bispecific antibody, alongside a portfolio of antibody-drug conjugates (ADCs) including PD-L1 and ITGB6-targeted candidates. The company aims to combine these therapies to create synergistic treatments for various solid tumors.
Themes: oncology therapeutics, bispecific antibodies, antibody-drug conjugates (ADCs), immuno-oncology, solid tumor treatments
Fundamentals
- Price$14.12 as of 2026-10-08 close
- Market cap$524M as of 2026-07-27 (share count; price 2026-10-08)
- 1-year return+17.1% 2025-10-08 close $12.06 → 2026-10-08 close $14.12
- P/En/a negative earnings
- Net margin-1419.6% FY2025, SEC XBRL
- ROE-75.8% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+413.7% as of 2026-09-03
- Beta1.10 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How CBIO compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CRESCENT BIOPHARMA INC looks technically
CRESCENT BIOPHARMA INC (CBIO) is trading 10.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 123 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 48.5% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 10.4% below its 200-day average, the long-term trend line — a long-term downtrend | -10.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.64 | $16.64 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.76 | $15.76 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 123 trading days ago — a "golden cross", a bullish long-term signal | 123 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 22.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 37.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($12.98 to $17.04) — its "stochastic" reading is 28 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 28.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $27.41 | $27.41 |
|---|---|---|
| From the 52-week high | it is 48.5% below its 52-week high (its highest price of the past year) | -48.5% |
| Above the 52-week low | it is 61.9% above its 52-week low (its lowest price of the past year) | +61.9% |
| Below the 52-week high | it is 48.5% below its highest point of the past year | 48.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $2605.00 (set on 2018-02-15) | $2605.00 |
| Given back of the 52-week move | over the past year its closes ranged ($8.94 to $26.98), and it has given back well over two thirds of its rise from last year’s low — 71% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.25 to $15.83. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 71.3% |
| From the all-time high | it is 99.5% below its all-time high | -99.5% |
| Nearest price level | it is trading 0.8% above a support level at $14.00 — a price it turned at twice since 2025-07-18, most recently on 2026-07-31. Since 2024-10-08 it has 6 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.8% |
| All-time low | its lowest closing price on record is $8.72 (set on 2026-02-09) | $8.72 |
| Above the all-time low | it is 61.9% above its all-time low | +61.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 70th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.24 between its high and its low — about 8.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.24 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.72 and $19.43 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.72 – $15.57 – $19.43 |
| Typical daily range (% of price) | its price moves about 8.8% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.8% |
| Stretch from the 200-day average | it is trading 1.3 daily ranges below its 200-day average price (10.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.61× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.9% since the prior reading | +2.9% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Gap filled | a 6.0% gap up opened on 2026-10-06 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 32.0 percentage points (the stock lost 31.0% while the market gained 1.0%) | -32.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.8 percentage points (the stock lost 16.0% while the market gained 3.8%) | -19.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 44.6 percentage points (the stock lost 27.1% while the market gained 17.5%) | -44.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 2.1 percentage points (the stock gained 17.1% while the market gained 15.0%) | +2.1% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.8% of the share price, which is taken to mean a barrier that gives way easily. | -14.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $16.48 — a volume-weighted average of daily closes over 193 sessions, not a true tick-by-tick VWAP. | -14.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% below the average price paid since it last reported on 2026-07-14 (its 8-K), so the typical buyer over that stretch is under water. That average is $16.36 — a volume-weighted average of daily closes over 62 sessions, not a true tick-by-tick VWAP. | -13.7% |
Price levels it has turned at before
CBIO last closed at $14.12 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.00 | Support | 0.8% below the last close | turned there twice · 2025-07-18 to 2026-07-31 |
| $14.81 | Resistance | 4.9% above the last close | turned there twice · 2026-01-21 to 2026-05-01 |
| $13.41 | Support | 5.1% below the last close | turned there five times · 2025-09-22 to 2026-09-24 |
| $16.06 | Resistance | 13.7% above the last close | turned there three times · 2025-08-26 to 2026-08-31 |
| $12.02 | Support | 14.9% below the last close | turned there twice · 2025-09-16 to 2025-11-03 |
| $16.44 | Resistance | 16.4% above the last close | turned there twice · 2025-12-04 to 2026-06-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · Analyst price target recently RAISED · lagging the market · Just filled a gap (5%+ closed in the last week) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.38 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$31.50 range $27.00 – $36.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CBIO
- Consensus EPS estimate-$0.57 next reporting period, as of 2026-10-07
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no commercial products and a history of operating losses.","Reliance on strategic partnerships, specifically with Kelun-Biotech, for key product development.","Substantial funding requirements to complete clinical trials and potential need for additional capital."]
What changed in the latest 10-Q
AI-assisted comparison of CBIO's 10-Q filed 2026-07-30 against the prior one filed 2026-04-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states in first quarter of 2026 the company initiated ASCEND and, through Kelun, a Phase 1/2 trial of CR-003 as a monotherapy in China.
- Newer filing adds that Kelun recently initiated a Phase 2 clinical study in China of sac-TMT in combination with CR-001 to evaluate safety, tolerability, and efficacy in patients with non-small cell lung cancer, with initial data anticipated in mid-2027 (second or third quarter).
- Newer filing adds initial standard of care chemotherapy combination data planned for mid-2027 (second or third quarter).
- Newer filing specifies the Kelun partnership announcement occurred in December 2025.
- Newer filing adds the July 2026 Offering to the list of funding sources.
- Newer filing adds net loss of $24.8 million for the three months ended June 30, 2026 and $48.1 million for the six months ended June 30, 2026.
- Newer filing adds accumulated deficit of $219.9 million as of June 30, 2026.
- Newer filing adds net cash used of $28.4 million for operating activities for the six months ended June 30, 2026.
- Newer filing adds cash and cash equivalents of $171.6 million as of June 30, 2026.
- Newer filing begins a Recent Developments section with heading 'At-The-Mar'.
- Removed:
- Older filing states ASCEND was initiated in February 2026.
- Older filing states the company anticipates initiation of a CR-002 monotherapy clinical trial in 2026 as well as the first ADC combination trial with CR-001 with initial data anticipated in mid-2027.
- Older filing describes the Kelun partnership announcement as 'recently announced' rather than specifying December 2025.
- Older filing lists funding sources as reverse recapitalization, Pre-Closing Financing, and Private Placement, without the July 2026 Offering.
- Older filing states net loss of $23.3 million for the three months ended March 31, 2026.
- Older filing states accumulated deficit of $195.1 million as of March 31, 2026.
- Older filing states net cash used of $8.9 million for operating activities for the three months ended March 31, 2026.
- Older filing states cash and cash equivalents of $189.2 million as of March 31, 2026.
- Older filing begins Recent Developments with 'Initiation of ASCEND Phase 1/2 Clinical Trial of CR-001' and states the first patient was dosed on February 18, 2026.
- Reworded:
- Newer filing replaces 'non-small cell lung cancer patients' with 'NSCLC patients' in the planned backfill cohort description.
- Newer filing changes the CR-003 partnership initiation statement from 'recently announced a partnership' to 'in December 2025, we announced a partnership'.
- Newer filing changes the CR-003 Phase 1/2 trial description by adding 'through our partner Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun")' to the first-quarter 2026 initiation statement, whereas older filing included this partner reference earlier in the same sentence.
- Notes:
- The newer filing text appears truncated in the Recent Developments section, ending with 'At-The-Mar'.
- Only the provided excerpts were compared; other portions of the MD&A may contain additional changes not included here.
Risk Factors
- Added:
- Newer filing (2026-07-30) changed 'with its ongoing activities' to 'with our ongoing activities' in the sentence about research and development expenses.
- Newer filing (2026-07-30) changed 'the current downturn in the U.S. capital markets' to 'a downturn in the U.S. capital markets'.
- Newer filing (2026-07-30) changed the cross-referenced risk factor title from 'Raising additional capital may cause dilution to our shareholders, restrict our operations, or require us to relinquish rights.' to 'Raising additional capital may cause additional dilution to our shareholders, restrict our operations, or require us to relinquish rights.'
- Newer filing (2026-07-30) has the table of contents page marker as page 40, while the older filing (2026-04-29) has it as page 37.
- Reworded:
- The word 'its' in the older filing (2026-04-29) was changed to 'our' in the newer filing (2026-07-30) in the sentence about research and development expenses.
- The phrase 'the current downturn' in the older filing (2026-04-29) was changed to 'a downturn' in the newer filing (2026-07-30).
- The cross-referenced risk factor title was changed from 'Raising additional capital may cause dilution to our shareholders, restrict our operations, or require us to relinquish rights.' in the older filing (2026-04-29) to 'Raising additional capital may cause additional dilution to our shareholders, restrict our operations, or require us to relinquish rights.' in the newer filing (2026-07-30).
- Notes:
- The newer filing text appears to be truncated at 'Even if one or more of the product candidates that we develop is approved for commercial sale, we', and no further text was provided, limiting comparison beyond this point.
- The older filing text also appears truncated at 'Even if one or more of the product candidates that we develop is approved for commercial sale, we', limiting comparison beyond this point.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 9 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 9 sells ($285501) — 7 selling insiders
- Last 90 days · read to 2026-10-041 buy ($12M) · 9 sells ($285501) — 1 buying, 7 selling insiders
- Last 180 days · read to 2026-10-041 buy ($12M) · 16 sells ($2M) — 1 buying, 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-18. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CBIO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
CBIO had 3,407,158 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CBIO had 9.17% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.51 days to cover at the same settlement.
- Reported short interest (shares) 3,407,158
- Short interest (% of shares outstanding) 9.17%
- Prior settlement (shares) 3,172,374
- Reported change 7.4%
- Days to cover (reported) 8.51
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK)
- AstraZeneca (AZN)
- Seagen (Pfizer) (PFE)
- Daiichi Sankyo (DSNKY)
- Gilead Sciences (GILD)
- ImmunoGen (AbbVie) (ABBV)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CBIO vs…
CRESCENT BIOPHARMA INC is found in…
CBIO ranks in…
Frequently asked questions
What does CRESCENT BIOPHARMA INC (CBIO) do?
Crescent Biopharma is a clinical-stage biotechnology company focused on developing oncology therapies. Its strategy centers on the development of CR-001, a PD-1 x VEGF bispecific antibody, alongside a portfolio of antibody-drug conjugates (ADCs) including PD-L1 and ITGB6-targeted candidates. The company aims to combine these therapies to create synergistic treatments for various solid tumors.
What sector is CRESCENT BIOPHARMA INC (CBIO) in?
CRESCENT BIOPHARMA INC (CBIO) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CRESCENT BIOPHARMA INC's (CBIO) competitors?
Notable peers of CRESCENT BIOPHARMA INC (CBIO) include Merck, AstraZeneca, Seagen (Pfizer), Daiichi Sankyo and Gilead Sciences. This peer set is informational only — not financial advice.
Is CRESCENT BIOPHARMA INC (CBIO) overbought or oversold right now?
CRESCENT BIOPHARMA INC (CBIO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CBIO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.